Effect of Radiation Therapy Techniques on Outcome in N3-positive IIIB Non-small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy
Jae Myoung Noh, Jin Man Kim, Yong Chan Ahn, Hongryull Pyo, BoKyong Kim, Dongryul Oh, Sang Gyu Ju, Jin Sung Kim, Jung Suk Shin, Chae-Seon Hong, Hyojung Park, Eonju Lee
Cancer Res Treat. 2016;48(1):106-114.   Published online 2015 Feb 12     DOI: https://doi.org/10.4143/crt.2014.131
Citations to this article as recorded by Crossref logo
Clinical Impact of Supraclavicular Lymph Node Involvement of Stage IIIC Non-Small Cell Lung Cancer Patients
Sunmin Park, Won Sup Yoon, Mi Hee Jang, Chai Hong Rim
Medicina.2021; 57(3): 301.     CrossRef
Salvage proton beam therapy for locoregional recurrence of non-small cell lung cancer
Hyunju Shin, Jae Myoung Noh, Hongryull Pyo, Yong Chan Ahn, Dongryul Oh
Radiation Oncology Journal.2021; 39(1): 24.     CrossRef
Comparaison dosimétrique et de la toxicité de la radiothérapie conformationnelle avec modulation d’intensité et de la radiothérapie conformationnelle tridimensionnelle des carcinomes bronchiques non à petites cellules
F. Guillemin, L. Berger, M. Lapeyre, A. Bellière-Calandry
Cancer/Radiothérapie.2021;[Epub]     CrossRef
Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer
Hyun Ae Jung, Jae Myoung Noh, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Hongryull Pyo, Yong Chan Ahn, Keunchil Park
Lung Cancer.2020; 146: 23.     CrossRef
Early blood rise in auto‑antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic‑non‑small cell lung cancer patients treated with PD‑1 immune‑check point blockade by nivolumab
Rocco Giannicola, Graziella D'Arrigo, Cirino Botta, Rita Agostino, Pietro Del Medico, Antonia Falzea, Vito Barbieri, Nicoletta Staropoli, Teresa Del Giudice, Pierpaolo Pastina, Valerio Nardone, Marika Monoriti, Graziella Calabrese, Giovanni
Molecular and Clinical Oncology.2019;[Epub]     CrossRef
Early tumor shrinkage served as a prognostic factor for patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy
Min Wei, Qingqing Ye, Xuan Wang, Men Wang, Yan Hu, Yonghua Yang, Jiyuan Yang, Jun Cai
Medicine.2018; 97(19): e0632.     CrossRef
Dosimetric advantages of intensity modulated radiation therapy in locally advanced lung cancer
John Boyle, Brad Ackerson, Lin Gu, Chris R. Kelsey
Advances in Radiation Oncology.2017; 2(1): 6.     CrossRef
Normal lung sparing Tomotherapy technique in stage III lung cancer
Chae-Seon Hong, Sang Gyu Ju, Yong Chan Ahn, Gyu Sang Yoo, Jae Myoung Noh, Dongryul Oh, Kwangzoo Chung, Hongryull Pyo, Kwanghyun Jo
Radiation Oncology.2017;[Epub]     CrossRef
Superior sulcus non-small cell lung carcinoma: A comparison of IMRT and 3D-RT dosimetry
Pierre Truntzer, Delphine Antoni, Nicola Santelmo, Catherine Schumacher, Pierre-Emmanuel Falcoz, Elisabeth Quoix, Gilbert Massard, Georges Noël
Reports of Practical Oncology & Radiotherapy.2016; 21(5): 427.     CrossRef
Cost of Intensity-modulated Radiation Therapy for Older Patients with Stage III Lung Cancer
Minal S. Kale, Grace Mhango, Marcelo Bonomi, Alex Federman, Keith Sigel, Kenneth E. Rosenzweig, Juan P. Wisnivesky
Annals of the American Thoracic Society.2016; 13(9): 1593.     CrossRef